Peptides DB
Research-centric peptide and protocol reference hub
Study 18 of 29Semaglutide literatureeuropepmc · Observational2026

<i>Parasutterella excrementihominis</i> is associated with attenuated metabolic improvements during obesity therapy in humans.

Parasutterella excrementihominis abundance decreased during weight loss therapy, correlating with improved insulin sensitivity, but its role in weight management remains uncertain.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
7
Preclinical
16
Observational · this one
0
Open-label
2
Randomised
4
Reviews

Summary and findings

This study measured the abundance of Parasutterella excrementihominis in 215 human subjects undergoing a non-surgical obesity therapy program. The study found that P. excrementihominis abundance decreased during the weight reduction phase and was positively correlated with improvements in insulin sensitivity. No treatment claims are made regarding the implications of these findings.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as europepmc supplied them

Alterations in the composition and function of the gut microbiome are important in obesity and type 2 diabetes development. Using our cross-sectional FoCus cohort, we recently found <i>Parasutterella</i> species were increased in human obesity and type 2 diabetes and linked to abnormalities in triglyceride metabolism and L-cysteine homeostasis, the latter being important for beta-cell function. To gain further insights, we now quantified gut <i>Parasutterella excrementihominis</i> by qPCR in <i>n </i>= 215 human subjects during an interdisciplinary non-surgical obesity therapy program consisting of an initial weight-reduction phase (weeks 1-12) followed by a weight-maintenance phase (weeks 13-26). <i>P. excrementihominis</i> abundance was significantly reduced during the weight reduction phase. While baseline abundance levels did not predict the success of weight-reduction, they were inversely associated with C-reactive-protein improvements. Interestingly, the decrease in <i>P. excrementihominis</i> abundance during the weight reduction phase was positively correlated with improvements in insulin sensitivity throughout the overall obesity intervention. Regarding the weight maintenance phase, a re-increase of <i>P. excrementihominis</i> abundance was significantly associated with weight regain. In summary, our data suggest that <i>P. excrementihominis</i> attenuates metabolic and inflammatory improvements in obese human subjects under therapy and highlight a potential role of this bacterial species in metabolic adaptation during weight loss interventions.

Elsewhere in the Semaglutide corpus

DCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026DEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026D1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.The lancet. Diabetes & endocrinology · 2026BComparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · 2026 · sleeve gastrectomy group had a BMI reduction difference of 4.04 kg/m² compared to the semaglutide group, p < 0.05HumanBGLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubesbiorxiv-preprint · 2026 · Semaglutide reduced glycolytic and total ATP production rates, exact values not reported.HumanBReal-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiographybiorxiv-preprint · 2026 · LV mass decreased from 198.4 ± 69.6 g to 176.6 ± 66.0 g in super-responders, p < 0.001.Human